Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.
CagriSema from Novo Nordisk combines GLP-1 RA semaglutide with long-acting amylin analogue cagrilintide
Additional details on phase 2 trial findings here and on the REDEFINE clinical trial program here.
CagriSema vs tirzepatide, ie, Novo Nordisk vs Lilly
Find additional details on the head-to-head study here and here.
Maritide (maridebart cafraglutide) from Amgen is a combined GLP-1 RA and GIP receptor antagonist
Find additional details on duration of effect and dosing here.
Monlunabant from Novo Nordisk is a cannabinoid receptor 1 inverse agonist shown to regulate metabolism and appetite.
Find additional details on monlunabant including the unique mechanism of action here.
APHD-012 from Aphaia Pharma is an oral glucose formulation designed to restore function of nutrient-sensing pathways throughout the GI tract.
Find additional details on the phase 2 development program here
Tern-601 from Tern Pharmaceuticals is an investigational oral small molecule GLP-1 RA that, if approved, will be administered once daily.
Find more information about Tern-601 and the phase 1 trial here.
Incretin analogues predominate among the 5 investigational weight management drugs highlighted in this slide show but an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are delivering commensurate results.
Development of medications to manage the metabolic dysregulation that drives overweight and obesity has become a bit of a blood sport, with hundreds of companies vying to deliver the next most effective molecule or combination of molecules that will modify the underlying pathology while producing negligible, or at least minimal, adverse effects.
Topline data for most of the 5 agents discussed in this slide show have been presented at professional society meetings over the past year and the companies behind them plan new readouts either late this year or in early-mid 2025. Information for the slide show was culled from the BioSpace website as well as manufacturer news.